We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+31.79%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$195M
AUM Growth
+$29.1M
Cap. Flow
-$4.32M
Cap. Flow %
-2.22%
Top 10 Hldgs %
80.78%
Holding
26
New
3
Increased
2
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$6.96M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$3.57M
3
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$2.35M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$383K
5
OCRX
Ocera Therapeutics, Inc.
OCRX
+$350K

Top Sells

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$7.36M
2
CHRS icon
Coherus Oncology
CHRS
+$3.54M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$2.83M

Sector Composition

Rank Sector Weight
1 Healthcare 88.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$42.7M 21.91%
1,035,657
– –
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.36B
$25.2M 12.95%
5,721,142
– –
PDSB icon
3
PDS Biotechnology
PDSB
$41.1M
$20.1M 10.33%
96,679
– –
ASND icon
4
Ascendis Pharma A/S
ASND
$17.1B
$14.5M 7.44%
721,152
– –
CTMX icon
5
CytomX Therapeutics
CTMX
$788M
$9.06M 4.65%
577,831
– –
BOLD
6
DELISTED
Audentes Therapeutics, Inc
BOLD
$7.27M 3.73%
+458,882
New +$6.96M
HRTX icon
7
Heron Therapeutics
HRTX
$89.1M
$6.99M 3.59%
405,901
– –
CLCD
8
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$6.07M 3.12%
+159,110
New +$2.35M
SIOX
9
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.01M 3.09%
53,699
– –
RGNX icon
10
Regenxbio
RGNX
$511M
$4.66M 2.39%
332,494
-667,139
-67% -$7.36M
ARCT icon
11
Arcturus Therapeutics
ARCT
$172M
$3.8M 1.95%
219,638
+11,866
+6% +$383K
ONC
12
BeOne Medicines Ltd
ONC
$32.4B
$3.67M 1.88%
119,000
– –
CHRS icon
13
Coherus Oncology
CHRS
$216M
$3.47M 1.78%
129,629
-129,630
-50% -$3.54M
STML
14
DELISTED
Stemline Therapeutics, Inc.
STML
$3.42M 1.76%
315,980
– –
ACHN
15
DELISTED
Achillion Pharmaceuticals
ACHN
$3.4M 1.75%
+420,000
New +$3.57M
AKTX
16
Akari Therapeutics
AKTX
$19.3M
$3.14M 1.61%
462
– –
ORKA
17
Oruka Therapeutics
ORKA
$5.59B
$3.05M 1.57%
4,995
– –
OCRX
18
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.87M 1.47%
1,088,372
+140,000
+15% +$350K
SYRE icon
19
Spyre Therapeutics
SYRE
$8.7B
$2.23M 1.15%
14,005
– –
LPCN icon
20
Lipocine
LPCN
$18.4M
$1.87M 0.96%
24,706
– –
ADVM
21
DELISTED
Adverum Biotechnologies
ADVM
$1.15M 0.59%
28,000
– –
LRMR icon
22
Larimar Therapeutics
LRMR
$384M
$468K 0.24%
11,790
– –
SRRA
23
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$238K 0.12%
3,270
– –
GBT
24
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-170,312
Closed -$2.83M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q3 2016 Portfolio in Review

As of Q3 2016, VHCP Management II held 26 positions worth $195M, up 18% from $166M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

VHCP Management II's Q3 2016 filing shows 3 new, 2 increased, 2 reduced and 2 closed positions. Its largest new stake was Audentes Therapeutics, Inc: 458,882 shares worth $7.27M. The largest sale was Regenxbio, an estimated $7.36M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier.

  • VHCP Management II's largest Q3 2016 buy was Audentes Therapeutics, Inc: 458,882 shares worth $7.27M.
  • VHCP Management II added most to Arcturus Therapeutics in Q3 2016, an estimated $383K increase.
  • VHCP Management II's biggest Q3 2016 reduction was Regenxbio, cutting an estimated $7.36M.
  • VHCP Management II fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $2.83M.
  • VHCP Management II's ten largest holdings make up 81% of its $195M portfolio in Q3 2016.
  • VHCP Management II opened 3 new positions and closed 2 in Q3 2016.
  • VHCP Management II's portfolio value rose 18% quarter-over-quarter to $195M.

Based on VHCP Management II's 13F filing for Q3 2016, filed 14 Nov 2016.